Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial (vol 9, pg 743, 2021)

被引：0
|
作者：
Heerspink, H. J. L.
Jongs, N.
Chertow, G. M.
机构：
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2022年 / 10卷 / 10期
关键词：
D O I：
10.1016/S2213-8587(22)00223-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [1] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Heerspink, Hiddo J. L.
    Jongs, Niels
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Greene, Tom
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 743 - 754
  • [2] The Effect of Dapagliflozin on Rate of Kidney Function Decline in Patients with CKD: A Prespecified Analysis from the DAPA-CKD Trial
    Heerspink, Hiddo J. L.
    Jongs, Niels
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Stefansson, Bergur V.
    Toto, Robert D.
    Wheeler, David C.
    Greene, Tom
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 35 - 36
  • [3] Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Jongs, Niels
    Greene, Tom
    Chertow, Glenn M.
    McMurray, John J., V
    Langkilde, Anna Maria
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 755 - 766
  • [4] DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL
    Jong, Niels
    Chertow, Glenn
    Hou, Fan Fan
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Stefansson, Bergur
    Toto, Robert
    Langkilde, Anna Maria
    Wheeler, David C.
    Heerspink, Hiddo Lambers
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [5] Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
    Wheeler, David C.
    Jongs, Niels
    Stefansson, Bergur, V
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    Langkilde, Anna Maria
    McMurray, John J., V
    Rossing, Peter
    Nowicki, Michal
    Wittmann, Istvan
    Correa-Rotter, Ricardo
    Sjostrom, C. David
    Toto, Robert D.
    Heerspink, Hiddo J. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (09) : 1647 - 1656
  • [6] Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial
    Chertow, Glenn M.
    Correa-Rotter, Ricardo
    Vart, Priya
    Jongs, Niels
    McMurray, John J. V.
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (09):
  • [7] Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    Wheeler, David C.
    Stefansson, Bergur, V
    Jongs, Niels
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Toto, Robert D.
    Sjostrom, C. David
    Langkilde, Anna Maria
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (01): : 22 - 31
  • [8] Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
    Marx, Nikolaus
    Floege, Juergen
    EUROPEAN HEART JOURNAL, 2021, 42 (13) : 1228 - 1230
  • [9] Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD
    Schechter, Meir
    Jongs, Niels
    Chertow, Glenn M.
    Mosenzon, Ofri
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 59 - +
  • [10] Effects of Dapagliflozin in Patients Without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial
    Heerspink, Hiddo J. L.
    Chertow, Glenn
    Jongs, Niels
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Langkilde, Anna Maria
    Wheeler, David C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 847 - 848
12345